Local researchers look to improve treatment for lung cancer patients

Cancer Research UK

Doctors from around the UK are taking part in one of the world's largest lung cancer clinical trials investigating how a blood thinning drug might help prevent blood clots in lung cancer patients.

The Cancer Research UK funded trial - named FRAGMATIC - is investigating whether a drug called Dalteparin can treat this problem and whether the drug may also improve the survival of lung cancer patients.

People with lung cancer are at an increased risk of blood clots in their veins because of chemotherapy, surgery, inactivity or the lung cancer itself. Clots can be dangerous and even fatal if they dislodge and travel to the lungs. They can also cause pain in the chest and breathlessness.

Dalteparin - also known as Fragmin - may also have an anticancer effect and lead to an improvement in quality of life and survival rates after the lung cancer diagnosis because it is thought that the blood thinning drug may affect how cancer cells spread through the blood stream, but this is not known for sure. This trial is designed to help answer these questions and to identify any possible side effects of using the drug in this situation.

The trial, which was created by Dr Fergus Macbeth and Dr Simon Noble at Velindre Hospital in Cardiff, is hoping to recruit 2,200 patients and is due to involve between 50 and 100 centres around the UK.

Dr Macbeth, the lead researcher on the trial, said: "Blood clots can be quite common in people who have lung cancer and may be dangerous. With this research, we hope to learn how to reduce the risk of this problem and improve the treatment for patients. We are working hard to find better and more effective ways to treat this difficult illness."

Kate Law, Cancer Research UK's clinical trials director, said: "Lung cancer remains the second most common cancer in the UK. It is vital we continue to research new treatments and also improve existing treatments for the disease. Clinical trials like FRAGMATIC are important in helping to do this and developing better treatments for patients."

For more information on the trial, please visit CancerHelp UK or call the Cancer Research UK cancer information nurses on 0808 800 4040.

For media enquiries please contact the Cancer Research UK press office on 020 7061 8300 or, out of hours, the duty press officer on 07050 264059.

Notes to Editor

Breast cancer is the most common cancer in the UK with more than 44,000 cases diagnosed annually.

Every year around 38,300 cases of lung cancer are diagnosed in the UK. Lung cancer causes around 33,500 deaths each year in the UK.

FRAGMATIC will recruit over 2,000 people in the UK. Everybody taking part in the trial will be put into one of two treatment groups by a computer.

Group 1 patients will have standard treatment for lung cancer.

Group 2 patients will have standard treatment for lung cancer and a dalteparin (Fragmin) injection once a day for 24 weeks. The injections will start as soon as possible after joining the trial and before starting any other cancer treatment. The trial team will show everyone how to give themself the injections.

About Cancer Research UK

  • Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
  • Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
  • Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
  • Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
  • Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
  • For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7009 8820 or visit our homepage.